Post by EU-Startups

STORM Therapeutics Limited, a Cambridge-based BioTech company targeting RNA modifications to reprogram cells and develop novel cancer therapies, today announced that it has secured €47.5 million in Series C financing. 🇬🇧 🧬💉 The financing was secured from existing investors, M Ventures, Pfizer Ventures, @Taiho Ventures LLC, IP Group plc, the UTokyo Innovation Platform Co., Ltd. (UTokyo IPC), and Fast Track Initiative (FTI). Jerry McMahon, Chief Executive Officer of STORM Therapeutics, said, “Advancing our first‑in‑class METTL3 inhibitor, STC-15, into Phase 2 clinical development marks a pivotal breakthrough in tackling cancers characterised by aberrant cell differentiation. This milestone highlights our scientific innovation and the potential to create new therapeutic options for patients with substantial unmet needs. https://lnkd.in/ghUiHKc2